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To the Editor, 
I read with great interest the recent publication by 
Tanrıöver  et  al.  on  splenic  artery  embolization,  in 
which they reached in conclusion that splenic artery 
embolization might be an option for hemolytic ane-
mia as a bridging therapy to surgery or as an alterna-
tive therapy, especially in critically ill patients with 
disorders  that  contraindicate  surgery  [1].  Partial 
splenic embolization (PSE) is a non-surgical proce-
dure developed to treat hypersplenism as a result of 
hepatic disease and thus avoid the disadvantages of 
splenectomy [2]. Furthermore, splenic artery emboli-
sation  has  been  used  to  treat  various  conditions, 
which include chronic idiopathic thrombocytopenic 
purpura, hereditary spherocytosis, and also splenic 
trauma in haemodynamically unstable patients. PSE 
provides a minimally invasive alternative to splenec-
tomy  in  patients  who  are  severely  compromised 
because  of  splenomegaly  or  sequestration  and 
destroying in the spleen. But, it should not be forgot-
ten  that  this  procedure  is  not  innocent.  There  are 
severe numerous complications of this method such 
as post infarction syndrome (fever, left upper quad-
rant pain, risk of infection and abscess formation), 
and embolization are related to migration or inap-
propriate placement of embolic material [3,4]. These 
are the most dangerous and lethal complications of 
the  procedure.  One  of  the  other  serious  potential 
complications associated with pulmonary disorders. 
Pneumonia, atelectasis, and pleural effusion, usually 
develop  in  the  left  lung  and  are  associated  with 
embolization of the upper pole of the spleen. Splenic 
abscesses,  rupture  of  the  spleen,  and  septicemia, 
have  been  previously  reported  after  PSE  [5]. 
Decreased portal-vein flow and a rapid increase in 
the platelet count after PSE may induce portal-vein 
thrombosis [2]. Moreover, the extent of embolization 
seems  to  be  critical  for  longterm  efficacy  of  PSE. 
Embolization of less than 50% of the splenic mass 
was  almost  always  associated  with  a  relapse  of 
hypersplenism or continuation of splenic activity [5]. 
Splenectomy  can  safely  be  performed  laparo-
scopically in almost all cases of primary autoimmune hemolytic anemia (AIHA), because the spleen is usu-
ally  of  normal  size  [6].  In  second-line  treatment, 
medical  reasons  in  favor  of  rituximab  are  relative 
contraindications for splenectomy such as massive 
obesity, technical problems, and a high risk of venous 
thromboembolism. A contraindication to rituximab 
treatment is an untreated hepatitis B virus infection. 
Additionally; intravenous immune globulin is not rec-
ommended for routine use in either acute or chronic 
treatment of AIHA. Based on consensus by the expert 
panel, IVIG may be considered among the options 
for treatment of severe life-threatening AIHA [7].
I propose that the process performed by Tanrıöver 
et al. should be applied only in selected patients with 
a very low preoperative level of hemoglobin and not 
susceptible to any hematologic and surgical conser-
vative treatment. Therefore; splenic artery embolisa-
tion preceding laparoscopic splenectomy should not 
be carried out routinely as appropriate use of blood 
products and correct surgical technique will be ade-
quate in controlling blood loss.
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Author Reply
Thank you for your comments and contribution. 
Complications  of  splenic  artery  embolization  have 
been very briefly discussed in this paper due to word 
count limitations. Indeed, all of the serious adverse 
events and complications that you have mentioned 
are to be considered while deciding to proceed with 
splenic  artery  embolization.  The  case  patient  had 
hemoglobin values as low as 1.4 g dL-1 and no com-
patible erythrocyte suspension could be obtained for 
several days, which lead the surgeons abstain from 
surgery.  Intravenous  immune  globulin  was  also 
administered because of this critical situation of the 
patient. Critical patients require critical, immediate 
and sometimes brave decisions in the intensive care 
unit. We think that splenic artery embolization was 
the  right  decision  regarding  the  challenges  of  the 
patient  presented.  Morever,  bleeding  could  not  be 
controlled during splenectomy which led to a fatal 
hypovolemic  shock,  making  us  think  what  would 
happen if the patient had not undergone surgery. We 
pointed out that “it might be a valuable option” for 
selected cases, but of course should not be the first 
line treatment for uncomplicated, low risk patients 
who are suitable for surgery. 
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